Development of membrane protein-based vaccine against lumpy skin disease virus (LSDV) using immunoinformatic tools.

Publisher: John Wiley & Sons Ltd Country of Publication: England NLM ID: 101678837 Publication Model: Print Cited Medium: Internet ISSN: 2053-1095 (Electronic) Linking ISSN: 20531095 NLM ISO Abbreviation: Vet Med Sci Subsets: MEDLINE

Original Publication: [Oxford] : John Wiley & Sons Ltd., [2015]-

Lumpy skin disease virus* ; Vaccines*; Animals ; Cattle ; Membrane Proteins ; Epitopes, T-Lymphocyte ; Immunoinformatics ; Molecular Docking Simulation ; Escherichia coli ; Protein Subunit Vaccines

Introduction: Lumpy skin disease, an economically significant bovine illness, is now found in previously unheard-of geographic regions. Vaccination is one of the most important ways to stop its further spread.
Aim: Therefore, in this study, we applied advanced immunoinformatics approaches to design and develop an effective lumpy skin disease virus (LSDV) vaccine.
Methods: The membrane glycoprotein was selected for prediction of the different B- and T-cell epitopes by using the immune epitope database. The selected B- and T-cell epitopes were combined with the appropriate linkers and adjuvant resulted in a vaccine chimera construct. Bioinformatics tools were used to predict, refine and validate the 2D, 3D structures and for molecular docking with toll-like receptor 4 using different servers. The constructed vaccine candidate was further processed on the basis of antigenicity, allergenicity, solubility, different physiochemical properties and molecular docking scores.
Results: The in silico immune simulation induced significant response for immune cells. In silico cloning and codon optimization were performed to express the vaccine candidate in Escherichia coli. This study highlights a good signal for the design of a peptide-based LSDV vaccine.
Conclusion: Thus, the present findings may indicate that the engineered multi-epitope vaccine is structurally stable and can induce a strong immune response, which should help in developing an effective vaccine towards controlling LSDV infection.
(© 2024 The Authors. Veterinary Medicine and Science published by John Wiley & Sons Ltd.)

Methods Mol Biol. 2015;1268:143-57. (PMID: 25555724)
Microb Pathog. 2021 Sep;158:105050. (PMID: 34146642)
Mol Biol Rep. 2019 Feb;46(1):511-527. (PMID: 30465133)
J Biomol Struct Dyn. 2021 Jul;39(10):3793-3801. (PMID: 32419646)
Amino Acids. 2013 Aug;45(2):257-68. (PMID: 23744401)
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W384-8. (PMID: 23737448)
Epidemiol Infect. 2013 Feb;141(2):425-30. (PMID: 22717050)
Bioinformatics. 2010 Dec 1;26(23):2936-43. (PMID: 20934990)
Front Vet Sci. 2021 Oct 26;8:721061. (PMID: 34765664)
BMC Vet Res. 2021 Jan 29;17(1):61. (PMID: 33514360)
BMC Res Notes. 2014 Feb 19;7:92. (PMID: 24552167)
PLoS One. 2020 May 13;15(5):e0232584. (PMID: 32401805)
Immunome Res. 2006 Apr 24;2:2. (PMID: 16635264)
Sci Rep. 2017 Aug 15;7(1):8285. (PMID: 28811600)
J Med Virol. 2021 Sep;93(9):5209-5211. (PMID: 33851735)
In Silico Pharmacol. 2021 May 11;9(1):36. (PMID: 33987075)
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W513-8. (PMID: 18515843)
ACS Omega. 2021 Nov 18;6(47):32043-32071. (PMID: 34870027)
Epidemiol Infect. 2001 Apr;126(2):317-21. (PMID: 11349983)
Infect Genet Evol. 2020 Nov;85:104472. (PMID: 32711078)
J Biomol Struct Dyn. 2022;40(23):12948-12963. (PMID: 34528491)
Mol Immunol. 2018 Dec;104:128-138. (PMID: 30448609)
Sci Rep. 2022 May 24;12(1):8736. (PMID: 35610299)
Proteins. 2003 Feb 15;50(3):437-50. (PMID: 12557186)
Acta Naturae. 2019 Apr-Jun;11(2):98-101. (PMID: 31413886)
Vet Res Commun. 2020 Nov;44(3-4):111-118. (PMID: 32857262)
Transbound Emerg Dis. 2008 Sep;55(7):263-72. (PMID: 18774991)
PLoS One. 2022 Aug 30;17(8):e0272582. (PMID: 36040967)
BMC Bioinformatics. 2013;14 Suppl 6:S4. (PMID: 23735058)
Vaccines (Basel). 2022 Sep 19;10(9):. (PMID: 36146643)
J Biomol Struct Dyn. 2021 Jan;39(1):219-235. (PMID: 31854239)
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1496-1503. (PMID: 31896580)
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W349-57. (PMID: 23748958)
BMC Bioinformatics. 2013 Dec 01;14:346. (PMID: 24289175)
BMC Bioinformatics. 2007 Jan 05;8:4. (PMID: 17207271)
J Mol Biol. 1978 Mar 25;120(1):97-120. (PMID: 642007)
Sci Rep. 2020 Jul 2;10(1):10895. (PMID: 32616763)
Sci Rep. 2022 Nov 12;12(1):19411. (PMID: 36371522)
Sci Rep. 2021 Jan 13;11(1):1249. (PMID: 33441913)
Sci Rep. 2017 Aug 23;7(1):9232. (PMID: 28835708)
Annu Rev Biophys Biomol Struct. 2006;35:115-33. (PMID: 16689630)
Sci Rep. 2022 Sep 25;12(1):15983. (PMID: 36156077)
Adv Sci (Weinh). 2021 Dec;8(24):e2102592. (PMID: 34719864)
Nucleic Acids Res. 2019 Jul 2;47(W1):W402-W407. (PMID: 31251384)
Tissue Antigens. 2003 Nov;62(5):378-84. (PMID: 14617044)
Sci Rep. 2019 Dec 27;9(1):20076. (PMID: 31882819)
Sci Rep. 2021 Feb 5;11(1):3238. (PMID: 33547334)
Sci Rep. 2019 Mar 13;9(1):4409. (PMID: 30867498)
Virus Res. 2019 Aug;269:197637. (PMID: 31152757)
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W407-10. (PMID: 17517781)
Front Immunol. 2022 Nov 09;13:933594. (PMID: 36439191)
Mol Microbiol. 2006 Apr;60(2):376-85. (PMID: 16573687)
PLoS One. 2013 Sep 13;8(9):e73957. (PMID: 24058508)
PLoS One. 2021 Feb 3;16(2):e0245072. (PMID: 33534822)
Sci Rep. 2019 Dec 24;9(1):19780. (PMID: 31874963)
Int J Pept. 2013;2013:197317. (PMID: 24027588)
Immunogenetics. 2015 Nov;67(11-12):641-50. (PMID: 26416257)
Proteins. 1993 Dec;17(4):355-62. (PMID: 8108378)
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W526-31. (PMID: 15980527)
J Virol. 2001 Aug;75(15):7122-30. (PMID: 11435593)
J Mol Biol. 2001 Jan 19;305(3):567-80. (PMID: 11152613)
ACS Omega. 2021 May 17;6(21):13742-13755. (PMID: 34095666)
Transbound Emerg Dis. 2022 Nov;69(6):3548-3561. (PMID: 36183192)
Vaccines (Basel). 2020 Mar 16;8(1):. (PMID: 32188062)
J Mol Model. 2014 Jun;20(6):2278. (PMID: 24878803)
Sci Rep. 2018 Jan 18;8(1):1125. (PMID: 29348555)
Sci Rep. 2017 Jul 31;7(1):6899. (PMID: 28761084)
J Virol. 2021 Apr 12;95(9):. (PMID: 33568514)
Nat Protoc. 2017 Feb;12(2):255-278. (PMID: 28079879)
Nat Rev Immunol. 2010 Nov;10(11):787-96. (PMID: 20948547)
Sci Rep. 2021 Oct 5;11(1):19707. (PMID: 34611250)
Microb Pathog. 2019 May;130:19-37. (PMID: 30822457)
Vaccines (Basel). 2021 Oct 06;9(10):. (PMID: 34696244)
Front Immunol. 2018 Dec 19;9:3000. (PMID: 30619353)
Gene. 2016 Jun 10;584(1):1-6. (PMID: 26945626)
Methods Enzymol. 1996;266:540-53. (PMID: 8743705)
Nat Protoc. 2021 Dec;16(12):5634-5651. (PMID: 34759384)
Bioinformatics. 2011 Oct 15;27(20):2843-50. (PMID: 21873636)
Front Immunol. 2021 Mar 02;12:621706. (PMID: 33737928)
PLoS One. 2010 Apr 16;5(4):e9862. (PMID: 20419125)
Bioinformatics. 2017 Oct 01;33(19):3098-3100. (PMID: 28575391)

Keywords: PET29a (+) vector; dynamic simulations; lumpy skin disease virus; membrane glycoprotein B and T cells; molecular docking; vaccine

0 (Membrane Proteins)
0 (Epitopes, T-Lymphocyte)
0 (Vaccines)
0 (Protein Subunit Vaccines)

Date Created: 20240331 Date Completed: 20240402 Latest Revision: 20240501

20240502

PMC10981917

10.1002/vms3.1438

38555573